Generate a tailored SOP for Dr. Melanie Kelly. Improve your application with a focused, well-structured draft.
Professor Kelly is the Executive Director of the International Cannabinoid Research Society and serves on the Board of the Canadian Consortium for the Investigation of Cannabinoids. She is also the Chief Scientific Officer at Panag Pharma Inc. in Halifax, Nova Scotia, Canada. Dr. Kelly's primary research expertise lies in translational pharmacology and drug discovery, focusing specifically on the pharmacology of the endocannabinoid system. Her work addresses how cannabis and cannabinoids can modify disease outcomes, particularly in neurodegenerative diseases. Throughout her career, she has published over 100 articles in the areas of pharmacology and cannabinoid research and holds patents related to cannabinoid drugs for therapeutic management of diseases. Dr. Kelly has played a significant role in developing medical and pharmacy curricula at undergraduate and graduate levels, contributing to continuing medical education and postgraduate professional education. She also actively consults within the industry on drug development related to the cannabis and cannabinoid space, working to translate scientific material for public knowledge.
Dalhousie University • Halifax, Nova Scotia, Canada
Professor in the Department of Pharmacology with a focus on translational pharmacology and cannabinoid research.